Biochips enable the accurate, rapid, and high-throughput detection of DNA, RNA, polypeptides, proteins, cells, tissues, and other biological components, with great advantages in disease screening and early diagnosis.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024.

Kidney dialysis firm Fresenius Medical Care said Monday that it is selling select laboratory assets to Quest Diagnostics.

The National Medical Products Administration (NMPA) has announced the priority review approval for Roche Diagnostics GmbH under its Priority Approval Procedure for Medical Devices (2016 No. 168).

Dutch diagnostics firm MRC Holland said this week that five of its blood-based tests for hereditary breast and ovarian cancer (HBOC) syndrome have received certification under Europe's In Vitro Diagnostic Regulation (IVDR).

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024.

Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications.

Manufacturing investments have taken center stage in recent years — from some pharma giants ramping up GLP-1 manufacturing capacity to meet soaring demand to other companies focusing on advanced capabilities that could ensure an adequate supply of vaccines.

Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. These capabilities are expected to drive expansion of spatial research and unlock applications and experiments that were previously not possible.

Recurrent spontaneous abortion (RSA) refers to the loss of the fetus 3 or more times before 28 weeks of gestation according to the usual definition in China, but it is also believed that the second consecutive procedure should be valued and evaluated.